Cargando…
Interstitial Lung Disease in a Patient Treated with Denosumab
Denosumab is an antiresorptive agent widely used for treating osteoporosis. Atypical femur fractures, osteonecrosis of the jaw and hypocalcaemia are well-known possible adverse effects of this drug. We present, to our knowledge, the first case report in the English literature of clinically significa...
Autores principales: | Ruiz, Ana Campo, Carrascosa, Miguel F, Concha, Sergio Tapia, Gil, Aníbal Hernández, Rivero, Juan García |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SMC Media Srl
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6663050/ https://www.ncbi.nlm.nih.gov/pubmed/31410352 http://dx.doi.org/10.12890/2019_001131 |
Ejemplares similares
-
Chondroblastoma’s Lung Metastases Treated with Denosumab in Pediatric Patient
por: Focaccia, Marco, et al.
Publicado: (2021) -
Cardiac tamponade as first manifestation of atrial angiosarcoma
por: Concha, Sergio Tapia, et al.
Publicado: (2019) -
One not to miss: Tuberculous tracheal stenosis
por: Ruiz, Ana Campo, et al.
Publicado: (2020) -
Effectiveness of Pulmonary Rehabilitation in Interstitial Lung Disease, Including Coronavirus Diseases: A Systematic Review and Meta-analysis
por: Reina-Gutiérrez, Sara, et al.
Publicado: (2021) -
Does denosumab offer survival benefits? —Our experience with denosumab in metastatic non-small cell lung cancer patients treated with immune-checkpoint inhibitors
por: Cao, Yenong, et al.
Publicado: (2021)